Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 6/2013

01-12-2013 | Original Article

ATG9A overexpression is associated with disease recurrence and poor survival in patients with oral squamous cell carcinoma

Authors: Jen-Yang Tang, Edward Hsi, Ya-Chun Huang, Nicholas Chung-Heng Hsu, Yuk-Kwan Chen, Pei-Yi Chu, Chee-Yin Chai

Published in: Virchows Archiv | Issue 6/2013

Login to get access

Abstract

ATG9A is an integral membrane protein required for autophagosome formation and a membrane carrier in the autophagy pathways. The present study was designed to investigate the expression of ATG9A in oral squamous cell carcinoma (OSCC). Clinically annotated tumor specimens from 90 patients with OSCC were subjected to immunohistochemistry using an antibody against ATG9A and immunoreactivity was scored using an immunoreactivity score (IRS). Scores were compared with clinical and pathologic data to assess association with outcome. Overexpression of ATG9A was defined as an IRS of ≥9 by receiver operating characteristics curve analysis and was identified in 25 (28 %) of 90 cases. ATG9A overexpression was associated with disease recurrence and overall survival (OS) in both univariate (p = 0.030 and 0.025, respectively) and multivariate (p = 0.026 and 0.038, respectively) Cox analyses. Kaplan–Meier plots also showed that patients with ATG9A overexpression had shorter 3-year OS (p = 0.017) and time to recurrence (p = 0.021) than those with low ATG9A expression. These results suggest that the presence of ATG9A in the cytoplasm of tumor cells may be an independent biomarker for disease recurrence and survival in patients with OSCC.
Literature
1.
Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49(8–31):31
2.
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
3.
Marino G, Lopez-Otin C (2004) Autophagy: molecular mechanisms, physiological functions and relevance in human pathology. Cellular and molecular life sciences : CMLS 61:1439–1454PubMedCrossRef
4.
Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6:463–477PubMedCrossRef
5.
6.
Suzuki K, Kirisako T, Kamada Y, Mizushima N, Noda T, Ohsumi Y (2001) The pre-autophagosomal structure organized by concerted functions of APG genes is essential for autophagosome formation. EMBO J 20:5971–5981PubMedCrossRef
7.
Krick R, Muehe Y, Prick T, Bremer S, Schlotterhose P, Eskelinen EL, Millen J, Goldfarb DS, Thumm M (2008) Piecemeal microautophagy of the nucleus requires the core macroautophagy genes. Mol Biol Cell 19:4492–4505PubMedCrossRef
8.
Sekito T, Kawamata T, Ichikawa R, Suzuki K, Ohsumi Y (2009) Atg17 recruits Atg9 to organize the pre-autophagosomal structure. Gene Cell: Devoted Mol Cell Mech 14:525–538CrossRef
9.
Young AR, Chan EY, Hu XW, Kochl R, Crawshaw SG, High S, Hailey DW, Lippincott-Schwartz J, Tooze SA (2006) Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. J Cell Sci 119:3888–3900PubMedCrossRef
10.
Yamada T, Carson AR, Caniggia I, Umebayashi K, Yoshimori T, Nakabayashi K, Scherer SW (2005) Endothelial nitric-oxide synthase antisense (NOS3AS) gene encodes an autophagy-related protein (APG9-like2) highly expressed in trophoblast. J Biol Chem 280:18283–18290PubMedCrossRef
11.
Yang ZJ, Chee CE, Huang S, Sinicrope FA (2011) The role of autophagy in cancer: therapeutic implications. Mol Canc Therapeut 10:1533–1541CrossRef
12.
Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, Nelson DA, Jin S, White E (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Canc Cell 10:51–64CrossRef
13.
Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891–2906PubMedCrossRef
14.
Mathew R, Karantza-Wadsworth V, White E (2007) Role of autophagy in cancer. Nature reviews. Cancer 7:961–967PubMed
15.
16.
Webber JL, Young AR, Tooze SA (2007) Atg9 trafficking in mammalian cells. Autophagy 3:54–56PubMed
17.
White E, DiPaola RS (2009) The double-edged sword of autophagy modulation in cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 15:5308–5316CrossRef
18.
Katayama M, Kawaguchi T, Berger MS, Pieper RO (2007) DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14:548–558PubMedCrossRef
19.
Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110:313–322PubMedCrossRef
20.
Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Investig 117:326–336PubMedCrossRef
21.
Li X, Fan Z (2010) The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Canc Res 70:5942–5952CrossRef
22.
Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM, Rabinowich H (2008) Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 283:19665–19677PubMedCrossRef
Metadata
Title
ATG9A overexpression is associated with disease recurrence and poor survival in patients with oral squamous cell carcinoma
Authors
Jen-Yang Tang
Edward Hsi
Ya-Chun Huang
Nicholas Chung-Heng Hsu
Yuk-Kwan Chen
Pei-Yi Chu
Chee-Yin Chai
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 6/2013
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1482-5

Other articles of this Issue 6/2013

Virchows Archiv 6/2013 Go to the issue

Original Article

Clinicopathologic characteristics and overall survival in patients with bladder cancer involving the gastrointestinal tract

Original Article

Expression of hypoxia-inducible factor 1 alpha in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis

Erratum

Erratum to: Early gallbladder carcinoma has a favorable outcome but Rokitansky–Aschoff sinus involvement is an adverse prognostic factor

Original Article

Monoclonal antibody HBME-1 reacts with a minor subset of B cells with villous surface and can be useful in the diagnosis of hairy cell leukemia and other indolent lymphoproliferations of villous B lymphocytes

Original Article

Detecting EGFR alterations in clinical specimens—pitfalls and necessities

Letter to the Editor

On the prevalence of KRAS mutations in GISTs